Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Travere Therapeutics, Inc.
< Previous
1
2
Next >
Travere Therapeutics to Present Abstracts at the Society for the Study of Inborn Errors of Metabolism Annual Symposium 2024
August 22, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
August 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Second Quarter 2024 Financial Results
August 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Second Quarter 2024 Financial Results
July 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference
July 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
May 09, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
May 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports First Quarter 2024 Financial Results
May 06, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report First Quarter 2024 Financial Results
April 29, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
April 24, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
CSLLY
TVTX
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
April 04, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
April 03, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 13, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
March 11, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at Upcoming Investor Conferences
February 26, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
February 23, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
ASX:CSL
CSLLY
TVTX
Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
February 15, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results
February 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference
February 01, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations
January 25, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Provides Corporate Update and 2024 Outlook
January 08, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 02, 2024
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
December 14, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
December 04, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
November 21, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Reports Third Quarter 2023 Financial Results
November 07, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
November 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
Travere Therapeutics to Report Third Quarter 2023 Financial Results
October 24, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Tickers
TVTX
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.